Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Praxis Precision Medicines, Inc. - Common Stock (NQ:PRAX)

342.50 +22.11 (+6.90%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	425,292
Open	326.26
Bid (Size)	325.37 (600)
Ask (Size)	364.00 (100)
Prev. Close	320.39
Today's Range	324.87 - 346.35
52wk Range	32.78 - 356.00
Shares Outstanding	44,712,538
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor

April 14, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026

April 13, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Performance

YTD	+19.6%	+19.6%
1 Month	+15.1%	+15.1%
3 Month	+5.7%	+5.7%
6 Month	+95.6%	+95.6%
1 Year	+869.2%	+869.2%

More News

Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy

April 06, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 02, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs

March 30, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges ↗

March 22, 2026

Via The Motley Fool

Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit ↗

March 18, 2026

Via The Motley Fool

This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗

March 16, 2026

Via The Motley Fool

This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal ↗

March 16, 2026

Via The Motley Fool

Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch ↗

March 16, 2026

Via The Motley Fool

This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter ↗

March 16, 2026

Via The Motley Fool

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? ↗

March 15, 2026

Via The Motley Fool

This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision ↗

March 13, 2026

Via The Motley Fool

Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug ↗

March 13, 2026

Via The Motley Fool

Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline ↗

March 13, 2026

Via The Motley Fool

This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough ↗

March 13, 2026

Via The Motley Fool

Battery Storage Stock Up 50% in a Year Draws New $110M Investment. Here's What You Should Know ↗

March 13, 2026

Via The Motley Fool

Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings ↗

March 13, 2026

Via The Motley Fool

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 04, 2026

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗

February 23, 2026

Via The Motley Fool

Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million ↗

February 22, 2026

Via The Motley Fool

Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗

February 22, 2026

Via The Motley Fool

Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗

February 22, 2026

Via The Motley Fool

$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗

February 22, 2026

Via The Motley Fool

Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock ↗

February 20, 2026

Via Stocktwits

Frequently Asked Questions

Is Praxis Precision Medicines, Inc. - Common Stock publicly traded?

Yes, Praxis Precision Medicines, Inc. - Common Stock is publicly traded.

What exchange does Praxis Precision Medicines, Inc. - Common Stock trade on?

Praxis Precision Medicines, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Praxis Precision Medicines, Inc. - Common Stock?

The ticker symbol for Praxis Precision Medicines, Inc. - Common Stock is PRAX on the Nasdaq Stock Market

What is the current price of Praxis Precision Medicines, Inc. - Common Stock?

The current price of Praxis Precision Medicines, Inc. - Common Stock is 342.50

When was Praxis Precision Medicines, Inc. - Common Stock last traded?

The last trade of Praxis Precision Medicines, Inc. - Common Stock was at 04/17/26 04:00 PM ET

What is the market capitalization of Praxis Precision Medicines, Inc. - Common Stock?

The market capitalization of Praxis Precision Medicines, Inc. - Common Stock is 15.31B

How many shares of Praxis Precision Medicines, Inc. - Common Stock are outstanding?

Praxis Precision Medicines, Inc. - Common Stock has 15B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.